ClinicalTrials.gg
RecruitingNCT06336395Updated Mar 28, 2024

Ma-Spore ALL 2020 Study

A Phase 2 interventional study of Prednisolone and Dexamethasone in B Lymphoblastic Leukemia, sponsored by National University Hospital, Singapore. Recruiting at 3 sites in 2 countries. Open to participants aged Up to 40 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by National University Hospital, Singapore · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Mar 2020, registered Mar 2024).
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
Up to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 5 open to participants now, 10 under way, 2 of them phase 3. Dasatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
5th of 41
500 · median 51
Started
2020
the only one that year
Phase 2
19 of 42
3 open now
Registered
41st of 42
by date

Among the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2020, is one of 19 in phase 2, and was the 41st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

5 of the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dasatinib

Dasatinib: first FDA approval 2006 (SPRYCEL), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.

Read the detailed description

This is a multicenter open-label phase II study involving children and young adult (\< 41 years old) who are newly diagnosed with B-ALL and treatment naïve. There will be 3 parallel cohorts whose risk to be stratified based upon leukemia genetics profiles and patient's treatment response:

  1. Standard Risk (SR)
  2. Intermediate Risk (IR)
  3. High Risk (HR)

All drugs being used are commercially available chemotherapy drugs. There will be no novel chemotherapeutic agent without marketing authorization being tested in this trial.

03

Conditions studied

  • B Lymphoblastic Leukemia
04

Who can participate

Ages eligible
Up to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has been diagnosed with B-lineage ALL as evidenced by:

    1. BMA blasts > 20% AND
    2. Leukemic process in the bone marrow, peripheral blood or any extra medullary tissue with confirmation of B-lymphoid differentiation by flow immunophenotyping or histopathologically
  2. Age \< 41 years of age at enrolment
  3. Written obtained from patient or legally acceptable representative (LAR)

Exclusion criteria

Exclusion Criteria:

  1. T-lineage ALL
  2. Down syndrome with ALL
  3. History of previous or this ALL is a second malignancy
  4. Mixed phenotype acute leukemia (MPAL) or undifferentiated leukemia
  5. Mature B-cell leukemia/lymphoma
  6. Any previous cytotoxic therapy (chemotherapy/radiotherapy/immunotherapy). Patient pre-treated with short term (\< 7 days of duration within last 1 month prior to ALL treatment start) may be enrolled after discussion and written approval from PI. These patients should be treated on at least intermediate arm.
  7. Persistent renal dysfunction with creatinine more than for age before start of induction therapy. Patients requiring temporary dialysis without persistent renal dysfunction can qualify.
  8. Liver dysfunction with direct > 10x upper normal limit for age.
  9. Any serious uncontrolled medical condition or impending end organ dysfunction that would impair the ability of the subject to receive protocol therapy
  10. Doubtful compliance or ability to complete study therapy due to financial, social, familial or geographic reason, or in the judgement of site investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Standard risk (SR)

    1. No anthracycline throughout the treatment. 2. CNS consolidation using "Capizzi type" low dose methotrexate (LDMTX) x 2 courses to replace pre-existing high dose methotrexate (HDMTX) 2.5g #3/4

    Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine

  • Experimental
    Intermediate risk (IR)

    Those with CD20 ≥ 20% expression on diagnostic blasts by flow immunophenotyping will receive additional dose of rituximab on day 1 of each delayed intensification (DI) phases: phase III (2 courses) and V (1 course) for total 3 infusions

    Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine · Drug: Rituximab · Drug: Doxorubicin

  • Experimental
    High risk (HR)

    Provisional HR patients will be offered CAR-T cell immunotherapy or HSCT

    Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Dasatinib · Drug: Imatinib · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine · Drug: Doxorubicin · Drug: Fludarabine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is calculated from the date of diagnosis to the date of last follow-up or any death

    Time frame: 5 years from diagnosis

Secondary outcomes

  1. Event free survival (EFS)

    EFS will be calculated from the date of diagnosis of ALL to date of last follow-up or to the first event, including relapse, resistant disease, second malignancy and death

    Time frame: 5 years from diagnosis

Other outcomes

  1. Cumulative incidence (CI) of relapse for all treated cohorts

    Time frame: 5 years from diagnosis

  2. Cumulative incidence (CI) of therapy-related mortality (TRM) for all treated subjects

    Time frame: 5 years from diagnosis

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Mar 2030, 120 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 120 months is above that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 28, 2024
StartActual
Mar 4, 2020
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2030
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336395
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Mar 4, 2020
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Mar 28, 2024

Study contacts

Allen Eng Juh Yeoh, MBBS
Contact
paeyej@nus.edu.sg
+65 67724406
Allen Eng Juh Yeoh, MBBS
principal investigator · Professor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dasatinib · Imatinib · Rituximab · Doxorubicin · Fludarabine

Start the discussion